ENTEREG Drug Patent Profile
✉ Email this page to a colleague
When do Entereg patents expire, and what generic alternatives are available?
Entereg is a drug marketed by Cubist Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has one patent family member in one country.
The generic ingredient in ENTEREG is alvimopan. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the alvimopan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Entereg
A generic version of ENTEREG was approved as alvimopan by WATSON LABS TEVA on December 19th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ENTEREG?
- What are the global sales for ENTEREG?
- What is Average Wholesale Price for ENTEREG?
Summary for ENTEREG
International Patents: | 1 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 158 |
Clinical Trials: | 16 |
Patent Applications: | 818 |
Drug Prices: | Drug price information for ENTEREG |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ENTEREG |
What excipients (inactive ingredients) are in ENTEREG? | ENTEREG excipients list |
DailyMed Link: | ENTEREG at DailyMed |
Recent Clinical Trials for ENTEREG
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Cleveland Clinic | Phase 4 |
Scott Steele | Phase 4 |
Brigham and Women's Hospital | Phase 3 |
US Patents and Regulatory Information for ENTEREG
ENTEREG is protected by one US patents.
Patents protecting ENTEREG
Methods of preventing and treating gastrointestinal dysfunction
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENTEREG
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ENTEREG
See the table below for patents covering ENTEREG around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 270039 | 4-PHENYLPIPERIDINO PROPANOIC ACID DERIVATIVES AND MEDICAMENTS | ⤷ Sign Up |
Norway | 178398 | ⤷ Sign Up | |
Israel | 111843 | Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparation | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |